| Identification | Back Directory | [Name]
Benzamide, 3-methoxy-N-[4-(1-pyrrolidinyl)phenyl]- | [CAS]
625403-59-0 | [Synonyms]
SBI-183
Benzamide, 3-methoxy-N-[4-(1-pyrrolidinyl)phenyl]- | [Molecular Formula]
C18H20N2O2 | [MOL File]
625403-59-0.mol | [Molecular Weight]
296.36 |
| Chemical Properties | Back Directory | [Boiling point ]
413.3±30.0 °C(Predicted) | [density ]
1.200±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.27±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo [1]. | [in vivo]
SBI-183 (786-O: 400 μg/mouse/day, p.o., 35 days; RCJ-41T2: 100 mg/kg, p.o., 21 days) inhibits tumor growth in two independent human xenograft mouse models of renal cell carcinoma[1].
| Animal Model: | Human xenograft mouse models of renal cell carcinoma (786-O and RCJ-41T2)[1] | | Dosage: | 400 μg/mouse/day (786-O); 100 mg/kg (RCJ-41T2) | | Administration: | Oral gavage (p.o.) | | Result: | Inhibited the growth of 786-O and RCJ-41T2 in vivo.
Reduced laminin-α4 deposition in RCJ-41T2 mouse xenografts.
|
| [References]
[1] Fifield, et al. Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular cancer therapeutics. 2020, 19(1), 112–122. DOI:10.1158/1535-7163.MCT-19-0233 |
|
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|